Instrument NameAllogene Therapeutics IncInstrument Symbol(ALLO-Q)

Instrument ExchangeNASDAQ

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

3 Stocks With Sky-High Short Interest Levels

Short Squeezes Have Returned in 2023 -- Here's Your Playbook

Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

Why Beam Therapeutics Stock Dipped Today

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

Allogene Therapeutics Reports First Quarter 2022 Financial Results

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology

Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update